LDS/Medical Tests/Coagulation Factor VII Activity Assay, Plasma

Coagulation Factor VII Activity Assay, Plasma

Factor VII (FVII) is a vitamin K-dependent serine protease synthesized in the liver. FVII is a part of the extrinsic coagulation cascade activated by thrombin, Factor Xa, or Factor IXa, which is then converted to Factor VIIa. The activated VIIa factor then converts phospholipid-bound Factor X into Factor Xa in the presence of calcium and tissue factor. It also converts Factor IX to Factor IXa. Factor VII deficiency may occur as an inherited or acquired disorder.

In inherited deficiency, such as congenital deficiency of factor VII, which is rare, the production of the protein might not be effected or might be reduced, but rarely absent. In other forms of inherited FVII, the production of protein might be normal, but the synthesized protein, might have abnormal or decreased activity. The decreased activity in heterozygotes is approximately 50%, whereas, in homozygotes, the activity of FVII is below 50% or even below 20%. However, the bleeding usually occurs when activity of the FVII is below 10%.

Acquired Factor VII deficiency also occurs in vitamin K deficiency and in patients taking warfarin therapy. It can also occur in deficiencies of Factors II, IX, and X, and in Disseminated intravascular coagulation or liver disease due to decreased synthesis. People with severe FVII deficiency might experience intracranial hemorrhage, joint and muscle bleeds, easy bruising and bleeds after surgery. Bleeds can also occur in the skin, mouth, nose and genitourinary tract. Women often experience severe menorrhagia (long, heavy periods).

  • Diagnosing congenital deficiency of coagulation factor VII
  • As an aid in diagnosis of acquired FVII deficiency associated with liver disease
  • As an aid in diagnosis of vitamin K deficiency * Monitoring anticoagulation therapy with warfarin

Heterozygotes generally have levels <= 50%.

Homozygotes have levels usually < 20%. Newborn infants usually have levels >= 25%.

Increased in: 

  • Type II Diabetes mellitus
  • Coronary artery disease
  • Hyperlipidemia 
  • Obesity

Decreased in:

  • Congenital deficiency of factor VII
  • Disseminated intravascular coagulation (DIC)
  • Fat malabsorption * Liver disease (such as cirrhosis)
  • Vitamin K deficiency
  • Warfarin (Coumadin) use
  • Hemophilia
Age Group Reference Range
1-7 days 28-110%
7-30 days 35-140%
30-89 days 42-140%
90-179 days 40-145%
180-364 days 47-130%
1-5 years 55-120%
6 years 52-120%
7-9 years 67-145%
10-11 years 71-163%
12-13 years 78-160%
14-15 years 74-180%
16-17 years 63-163%
18 years and older 80-181%

Thrombin clot based assay.

Plasma (blue top tube). 

Stability

  • Ambient: 4 hours
  • Refrigerated: Unacceptable
  • Frozen: 2 weeks
Factor VII mixing studies, AST, ALT, Bilirubin, CMP, Liver Panel, Vitamin K levels, Factor VII inhibitor screening (Bethesda titers if indicated), Factor IX, Factor X.

1-3 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Semin Thromb Hemost. 2009 Jun;35(4):400-6. [PMID: 19598068]
  •  Haemophilia. 2008 Nov;14(6):1170-5. [PMID: 19141157]
  •  Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S47-54. [PMID: 14567537]
  •  Mini Rev Med Chem. 2006 Oct;6(10):1111-7. [PMID: 17073711]
  •  Semin Thromb Hemost. 2009 Jun;35(4):439-46. [PMID: 19598072]
  •  Feinstein DI: Acquired inhibitors of blood coagulation. In Hematology: Basic Principles and Practice. Edited by R Hoffman, EJ Benz Jr, SJ Shattil, et al. New York, Livingstone Press, 1991, pp 1380-1394.